News & Updates

Meta-analysis backs amisulpride for depression

17 Jun 2021 by

The second-generation antipsychotic amisulpride performs well in the treatment of depression and associated symptoms in individuals with a major mental health disorder, with efficacy and tolerability profiles similar to those of selective serotonin reuptake inhibitors and tricyclic antidepressants, as suggested in a meta-analysis of randomized controlled trials.

Meta-analysis backs amisulpride for depression

17 Jun 2021

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

15 Jun 2021

New drug applications approved by US FDA as of 01-15 June 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

15 Jun 2021

Unrealistic standards for success drive youth depression in Singapore

15 Jun 2021 by

Most young people in Singapore regard depressive disorders as a “reduced state of being” due to living a life that falls short of often unrealistic societal expectations, according to a recent study.

Unrealistic standards for success drive youth depression in Singapore

15 Jun 2021

Exercise, psychotherapy help boost effectiveness of antidepressants post-CAD

14 Jun 2021 by

Antidepressants remain the most understood treatment modality for depression after coronary artery disease (CAD), though emerging evidence suggests that combining them with psychotherapy and exercise seems to improve effectiveness, according to a recent network meta-analysis.

Exercise, psychotherapy help boost effectiveness of antidepressants post-CAD

14 Jun 2021

Naltrexone looks good for borderline personality disorder

07 Jun 2021 by

The opioid antagonist naltrexone helps reduce symptoms in patients with borderline personality disorder, with the effect dictated by dose and superior to all available psychoactive drugs, as shown in a study.

Naltrexone looks good for borderline personality disorder

07 Jun 2021

Obsessive-compulsive disorder carries increased stroke hazard

06 Jun 2021

Patients with obsessive-compulsive disorder are at heightened risk of developing new-onset ischaemic stroke later in life, a study reports.

Obsessive-compulsive disorder carries increased stroke hazard

06 Jun 2021

Using CCTVs, video in the fight against suicide

04 Jun 2021 by

Closed-circuit television (CCTV) and video systems have seen growing use in the prevention of suicide, particularly for the early detection of preattempts, according to a new study.

Using CCTVs, video in the fight against suicide

04 Jun 2021

Internet-delivered CBT effective for youths with social anxiety disorder

03 Jun 2021

A 10-week course of internet-delivered cognitive behavioural therapy (ICBT) is an efficacious and cost-effective intervention for children and adolescents with social anxiety disorder (SAD) compared with internet-delivered supportive therapy (ISUPPORT), results of a recent randomized clinical study have shown.

Internet-delivered CBT effective for youths with social anxiety disorder

03 Jun 2021

Mental health recovery slow during COVID-19 pandemic

03 Jun 2021

Mental health of most adults in the UK remained resilient or returned to around the same level prior to the coronavirus disease 2019 (COVID-19) pandemic, although around one in nine had deteriorating or consistently poor mental health, results of a recent latent class trajectory analysis have shown.

Mental health recovery slow during COVID-19 pandemic

03 Jun 2021

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

02 Jun 2021

New drug applications approved by US FDA as of 16-31 May 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

02 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Meta-analysis backs amisulpride for depression

Meta-analysis backs amisulpride for depression

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

Original New Drug Application Approvals by US FDA (01 - 15 June 2021)

Unrealistic standards for success drive youth depression in Singapore

Unrealistic standards for success drive youth depression in Singapore

Exercise, psychotherapy help boost effectiveness of antidepressants post-CAD

Exercise, psychotherapy help boost effectiveness of antidepressants post-CAD

Naltrexone looks good for borderline personality disorder

Naltrexone looks good for borderline personality disorder

Obsessive-compulsive disorder carries increased stroke hazard

Obsessive-compulsive disorder carries increased stroke hazard

Using CCTVs, video in the fight against suicide

Using CCTVs, video in the fight against suicide

Internet-delivered CBT effective for youths with social anxiety disorder

Internet-delivered CBT effective for youths with social anxiety disorder

Mental health recovery slow during COVID-19 pandemic

Mental health recovery slow during COVID-19 pandemic

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)